{"title":"Alternatives to positive airway pressure devices for obstructive sleep apnea: a phenotype-guided review.","authors":"Abdulghani Sankari","doi":"10.1080/17476348.2026.2738234","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Continuous positive airway pressure (PAP) is the reference treatment for obstructive sleep apnea (OSA); however, limited adherence leaves many patients inadequately treated, creating a pressing need for effective alternatives matched to individual disease mechanisms.</p><p><strong>Areas covered: </strong>This review examines the principal alternatives to PAP - custom oral appliances, upper airway and adherence-directed surgery, hypoglossal nerve stimulation, positional therapy, myofunctional and respiratory muscle training, daytime neuromuscular stimulation, neuromuscular pharmacotherapy, and weight-directed incretin therapy in adults. For each, we summarize indications, evidence, and limitations, and integrate drug-induced sleep endoscopy, bedside functional testing, and physiological endotyping into candidate selection. PubMed/MEDLINE and the Cochrane Library were searched from January 2005 through July 2026 using combinations of 'obstructive sleep apnea,' 'CPAP alternative,' 'phenotype,' 'endotype,' 'drug-induced sleep endoscopy,' and each modality's name; pivotal randomized trials, current clinical practice guidelines, and mechanistic studies from high-impact journals were prioritized, supplemented by hand-searching reference lists.</p><p><strong>Expert opinion: </strong>OSA care is shifting from a one-size-fits-all model toward phenotype-guided precision management. The first approved drug therapy, the maturation and broadening of hypoglossal nerve stimulation, and endotype-targeted pharmacotherapy will make mechanism-based selection and rational combination therapy the central task for clinicians treating patients unable to use PAP.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-14"},"PeriodicalIF":2.7000,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2026.2738234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Continuous positive airway pressure (PAP) is the reference treatment for obstructive sleep apnea (OSA); however, limited adherence leaves many patients inadequately treated, creating a pressing need for effective alternatives matched to individual disease mechanisms.
Areas covered: This review examines the principal alternatives to PAP - custom oral appliances, upper airway and adherence-directed surgery, hypoglossal nerve stimulation, positional therapy, myofunctional and respiratory muscle training, daytime neuromuscular stimulation, neuromuscular pharmacotherapy, and weight-directed incretin therapy in adults. For each, we summarize indications, evidence, and limitations, and integrate drug-induced sleep endoscopy, bedside functional testing, and physiological endotyping into candidate selection. PubMed/MEDLINE and the Cochrane Library were searched from January 2005 through July 2026 using combinations of 'obstructive sleep apnea,' 'CPAP alternative,' 'phenotype,' 'endotype,' 'drug-induced sleep endoscopy,' and each modality's name; pivotal randomized trials, current clinical practice guidelines, and mechanistic studies from high-impact journals were prioritized, supplemented by hand-searching reference lists.
Expert opinion: OSA care is shifting from a one-size-fits-all model toward phenotype-guided precision management. The first approved drug therapy, the maturation and broadening of hypoglossal nerve stimulation, and endotype-targeted pharmacotherapy will make mechanism-based selection and rational combination therapy the central task for clinicians treating patients unable to use PAP.